Unknown PHASE1 NCT00002449

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

A Bridging Dose-Escalation Study of the Safety, Pharmacokinetic Properties, and Immunologic Effect of Subcutaneous L2-7001 (Recombinant Human Interleukin-2) in Patients Infected With HIV With CD4+ T-Cell Counts of 300 to 500 Cells/mm3 and Viral Burden Under 10,000 Copies/Ml on Active Antiretroviral Therapy (ART)

Sponsor: Chiron Corporation

Conditions HIV Infections

Interventions Aldesleukin

Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Aug 31, 1999

A PHASE1 clinical study on HIV Infections, this trial is ongoing. The trial is conducted by Chiron Corporation and has accumulated 6 data snapshots since 1999. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiron Corporation

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Austin, United States , Beverly Hills, United States , Birmingham, United States , Boston, United States , Chicago, United States , Coral Gables, United States , Dallas, United States , Denver, United States , Fountain Valley, United States and 11 more locations